Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5(9):558–567
2. Wanis H (2014) HCV treatment in Egypt—why cost remains a challenge? Egyptian initiative for personal rights, Cairo, Egypt, pp 1–4. https://eipr.org/en/publications/hepatitis-c-treatment-egypt-why-cost-remains-challenge. Accessed on 27 Aug 2018
3. Waked I, Doss W, El-Sayed M (2014) The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol 15(2):45–52
4. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN et al (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368(20):1878–1887
5. Jacobson I, Gordon S, Kowdley K, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E et al (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368(20):1867–1877
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献